Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Seelos Therapeutics, Inc. (SEEL : NSDQ)
 
 • Company Description   
Seelos Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focused on the development and advancement of novel therapeutics to address unmet medical needs for central nervous system disorders. The company's product pipeline consists of SLS-002, SLS-006, SLS-008, SLS-010 and SLS-012 which are in clinical stage. Seelos Therapeutics Inc., formerly known as Apricus Biosciences Inc., is based in New York, United States.

Number of Employees: 16

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.63 Daily Weekly Monthly
20 Day Moving Average: 1,155,619 shares
Shares Outstanding: 106.09 (millions)
Market Capitalization: $66.84 (millions)
Beta: 2.62
52 Week High: $3.59
52 Week Low: $0.48
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -8.34% 0.37%
12 Week -40.57% -33.20%
Year To Date -61.35% -52.78%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
300 PARK AVENUE 12TH FLOOR
-
NEW YORK,NY 10022
USA
ph: 646-293-2100
fax: 858-436-8155
anthony.marciano@seelostx.com http://www.seelostherapeutics.com
 
 • General Corporate Information   
Officers
Raj Mehra - Chief Executive Officer;Chairman of the Board
Michael Golembiewski - Chief Financial Officer
Margaret Dalesandro - Director
Brian Lian - Director
Daniel J. O'Connor - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 81577F109
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/22
Next Expected EPS Date: 08/08/22
Share - Related Items
Shares Outstanding: 106.09
Most Recent Split Date: 1.00 (0.03:1)
Beta: 2.62
Market Capitalization: $66.84 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.30 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.90 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 08/08/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 1.46
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: 53.57%
vs. Previous Quarter: -%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -91.66
12/31/21 - -108.32
09/30/21 - -95.24
ROA
03/31/22 - -72.83
12/31/21 - -86.95
09/30/21 - -75.72
Current Ratio
03/31/22 - 6.98
12/31/21 - 10.07
09/30/21 - 10.07
Quick Ratio
03/31/22 - 6.98
12/31/21 - 10.07
09/30/21 - 10.07
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - 0.43
12/31/21 - 0.56
09/30/21 - 0.71
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - 0.33
12/31/21 - 0.31
09/30/21 - 0.00
Debt-to-Capital
03/31/22 - 24.65
12/31/21 - 23.79
09/30/21 - 0.00
 

Powered by Zacks Investment Research ©